South Korea has established itself as a leading biotechnology hub in Asia, with a particularly strong focus on neuroscience and neurodegenerative disease research. The Korean pharmaceutical and biotech sector has made significant strides in developing novel therapeutics for Parkinson's disease, including cell therapy, gene therapy, small molecule inhibitors, and biologics approaches[1].
The Korean government has prioritized neuroscience research through various initiatives, including the Korea Drug Development Fund (KDDF), the K-BIO cluster development program, and partnerships between academic institutions and pharmaceutical companies. This supportive ecosystem has enabled Korean biotechnology companies to advance innovative Parkinson's disease therapies through clinical development[2].
Samsung Bioepis has expanded beyond its biosimilar foundation to develop novel immunotherapeutics for neurodegenerative diseases. Their approach focuses on modulating the immune response to reduce neuroinflammation, a key pathological feature of Parkinson's disease. The company has established partnerships with international biotech firms to access cutting-edge immunotherapy platforms.
CJ Healthcare has leveraged its expertise in gastrointestinal therapeutics to develop CNS drugs that can cross the blood-brain barrier. Their Parkinson's disease program focuses on novel dopamine receptor agonists with improved side effect profiles compared to existing therapies. The company has conducted Phase 1 clinical trials for their lead PD candidate[3].
Kolon Life Science is a leader in cell and gene therapy in Korea. Their Parkinson's disease program includes:
The company has completed preclinical studies and is preparing for clinical trials in partnership with international pharmaceutical companies[4].
Genexine specializes in fusion protein technology and has developed a platform for long-acting biologics. Their Parkinson's disease approach includes:
The company has published preclinical data showing efficacy in animal models of Parkinson's disease[5].
Daewoong Pharmaceutical has invested heavily in advanced therapy development for Parkinson's disease:
The company operates a state-of-the-art cell therapy manufacturing facility meeting international GMP standards[1:1].
Bukwang Pharmaceutical has a established portfolio in CNS disorders:
The company has completed multiple Phase 2 clinical trials for their Parkinson's disease pipeline[7].
JW Pharmaceutical focuses on innovative drug development with an emphasis on CNS disorders. Their Parkinson's disease research includes:
Dong-A ST has developed a diversified pharmaceutical portfolio with growing CNS capabilities:
Yuhan Corporation invests significantly in CNS drug discovery:
Hanmi Pharmaceutical is one of Korea's largest pharmaceutical companies with a broad pipeline:
Japan has several biotechnology companies developing Parkinson's disease therapies that collaborate with Korean partners or have regional presence in East Asia.
Tree Pharmaceutical is an Osaka-based biotechnology company dedicated to developing novel therapeutics for neurodegenerative diseases. The company focuses on amyloid-beta and alpha-synuclein targeting approaches, leveraging Japan's strong academic research base to advance novel drug candidates through clinical development.
Accerise is a Tokyo-based drug discovery company utilizing structure-based design and computational approaches to develop therapeutics for neurodegenerative diseases. The company's proprietary platform enables rapid optimization of drug candidates targeting previously undruggable proteins involved in neurodegeneration.
Kinevo is a Tokyo-based biotechnology company focused on developing therapeutics targeting mitochondrial dysfunction in neurodegenerative diseases. Mitochondrial dysfunction is increasingly recognized as a central mechanism in both Alzheimer's and Parkinson's disease pathogenesis, making this a high-value target area.
CureApp is a Tokyo-based company developing digital therapeutics (DTx) for Alzheimer's disease and Parkinson's disease. The company takes a software-as-medical-device approach, developing smartphone-based interventions that can modify disease progression through cognitive training, behavioral modification, and remote monitoring.
Korean venture capital firms have shown increasing interest in biotech and neurodegenerative disease companies:
The Korean government supports neurodegenerative disease research through:
| Theme | Companies | Stage | Approach |
|---|---|---|---|
| Cell Therapy | Kolon Life Science, Daewoong | Clinical | Stem cell replacement |
| Gene Therapy | Kolon Life Science, Genexine | Preclinical/Clinical | AAV delivery |
| Small Molecules | Bukwang, JW Pharmaceutical | Various | Novel mechanisms |
| Immunotherapy | Samsung Bioepis, Genexine | Preclinical | Neuroinflammation |
Korean companies have established international partnerships:
Korean clinical trial infrastructure supports Parkinson's disease research:
Korean institutions have contributed to important clinical findings:
Korean biotechnology companies are pursuing several cutting-edge approaches:
Kim J, Park SH, Lee HJ. Cell therapy for Parkinson's disease: current status and future perspectives in Korea. Journal of Korean Medical Science. 2023. ↩︎ ↩︎
Korean Biotechnology Association. Korean Biotech Companies in Neuroscience. K-BIO Annual Report. 2025. ↩︎
Son GH, Kim JH, Lee YS. Dopamine agonist development by Korean pharmaceutical companies. Korean Journal of Pharmacology. 2023. ↩︎
Lee HJ, Kim SH, Park KH. Stem cell therapy for Parkinson's disease: Korean multicenter trials. Stem Cell Research & Therapy. 2022. ↩︎
Han JW, Lee CS, Park JS. Neuroinflammation targeting therapies in Korean drug development. Korean Journal of Inflammation. 2024. ↩︎
Kim YH, Park JS, Lee HJ. COMT inhibitors development by Korean pharmaceutical industry. Korean Journal of Clinical Pharmacy. 2022. ↩︎
Jung SY, Park JH, Choi DH. Clinical trials for Parkinson's disease in Korea: 2015-2024. Journal of Clinical Neurology. 2024. ↩︎ ↩︎
Yang MH, Kim HJ, Lee SY. Parkinson's disease biomarker research in Korea. Journal of Parkinson's Disease. 2023. ↩︎ ↩︎